Deciphera Pharmaceuticals Introduces Novel Drug in NCCN Guidelines
Deciphera Pharmaceuticals has recently announced the addition of its innovative drug, QINLOCK® (ripretinib), to the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology.
This inclusion designates QINLOCK® as a preferred treatment option for second-line gastrointestinal stromal tumor (GIST) patients who are unable to tolerate sunitinib.
This recognition by the NCCN® highlights the effectiveness and significance of QINLOCK® in managing GIST in patients who have experienced intolerance to sunitinib. The incorporation of QINLOCK® into the NCCN® guidelines emphasizes its potential to improve patient outcomes and offers healthcare professionals an important therapeutic choice when treating GIST.
Deciphera Pharmaceuticals has recently announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for QINLOCK®, their switch-control inhibitor. This designation applies to the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumor (GIST) who have previously received imatinib and possess a KIT exon 11 mutation, as well as concurrent KIT exon 17 and/or 18 mutations (KIT exon 11+17/18 mutations).
QINLOCK® has gained approval in 12 territories worldwide, including prominent markets such as the United States, Europe, and China, for its application in fourth-line GIST treatment. This significant recognition by the FDA through the Breakthrough Therapy Designation reinforces the potential of QINLOCK® as an important therapeutic option for patients with advanced GIST who have exhausted previous treatment options.
